3 papers in the library · 1 citation · publishing 2025-2026
BJPsych Open May 13, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
BJPsych Open February 16, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. 1 citation
BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
November 16, 2025 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. preprint
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...